Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Novartis is one of the world's top pharmaceutical ... France, England, Italy, Russia and the US. By 1884, Bindschedler & Busch had transformed into a joint-stock company and was renamed ...

Novartis CEO Vas Narasimhan discusses the company's quarterly earnings as the drugmaker lifted profit guidance for a third ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

A bitter and bloody war in Ukraine has devastated the country, further isolated Russia from the West and fueled economic insecurity around the world. Officials said more than 30 drones had been ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication. The Swiss drugmaker ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Russians close to the Kremlin voiced optimism that Donald J. Trump could help end the war in Ukraine on Russia’s terms. Vladimir V. Putin said Mr. Trump’s remarks on ending the war “deserve ...

Swiss pharmaceutical giant Novartis reported another solid quarter on Tuesday, raising its guidance for the third time this year. Yet its shares were the worst performers among big pharma ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...